Cramer's Market Picks: Palantir to $200, Viking Therapeutics a No-Go

Jim Cramer discusses various stocks in his Lightning Round, recommending Palantir and Richtech Robotics, but advising against Viking Therapeutics. He expresses concerns about Gartner's recent earnings and suggests waiting to see how the company performs in the future. Cramer emphasizes the importance of speculating wisely and being prepared for potential losses.

In his latest Lightning Round on "Mad Money," Jim Cramer provided swift insights into several stocks. Cramer recommended Palantir and Richtech Robotics, while advising caution with Viking Therapeutics. He also expressed concerns about Gartner's recent earnings performance.

Palantir Technologies (PLTR) received a bullish outlook from Cramer, who predicted the stock could reach $200. This optimism is likely driven by the company's strong year-to-date performance and its potential in the data analytics and AI sectors. Cramer advised that investors should be prepared for the risk of loss when speculating on stocks.

Richtech Robotics (RICH) was also recommended by Cramer, but with a cautionary note. He advised investors to recognize the speculative nature of the stock and be prepared for the possibility of losing their entire investment. This suggests that Cramer views Richtech Robotics as a high-risk, high-reward opportunity.

Viking Therapeutics (VKTX) was the subject of Cramer's most negative advice. He bluntly stated "No" to the stock, indicating his concerns about its prospects. This could be due to recent underperformance or other factors that Cramer believes make the stock a poor investment.

Gartner (IT) received mixed reviews from Cramer. He expressed his longstanding affection for the stock but noted that recent earnings left much to be desired. Cramer advised investors to wait and see how Gartner performs in the future before making any investment decisions.

Overall, Cramer's Lightning Round provided a mix of positive and negative insights into several stocks. His advice underscores the importance of careful consideration and risk assessment when investing in the stock market.

References:
[1] https://www.cnbc.com/2025/09/04/cramers-lightning-round-no-to-viking-therapeutics.html